NNVC ▲ +4.0% - NanoViricides, Inc.
$NNVC - NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
29-SEP-2026 08:45 AM ET
Share this post
More filings for $NNVC
NNVC ▼ -2.1% - NanoViricides, Inc.Sep 28, 2026NNVC ▲ +5.2% - NanoViricides, Inc.Sep 23, 2026NNVC ▼ -0.9% - NanoViricides, Inc.Sep 8, 2026NNVC ▼ -0.8% - NanoViricides, Inc.Aug 31, 2026
View full $NNVC filing history →💬 Comments
Loading comments…
Leave a comment